PillInjection, Suspension · Intramuscular
Influenza A Virus A/Tasmania/318/2025 Cvr-351 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/Tasmania/787/2025 Cvr-388 (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/Arizona/21/2025 Antigen (Mdck Cell Derived, Propiolactone Inactivated)
Brands: Flucelvax · Influenza A Virus A/Tasmania/318/2025 Cvr-351 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated) + Influenza A Virus A/Tasmania/787/2025 Cvr-388 (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated) + Influenza B Virus - B/Arizona/21/2025 Antigen (Mdck Cell Derived, Propiolactone Inactivated)
0 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US1 NDCs
0 active makers
0 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)2740125
US makers1 labelers
Packages1
DEA / ScheduleNone
Medicaid dispensing volume
No Medicaid utilization on record for this drug concept yet. Quarterly volume (CMS State Drug Utilization Data) loads with the utilization ETL.
Who makes it0 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Seqirus Inc. | unknown | 1 | EXITED 2027 |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.